Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.

Frontiers in immunology - 1 Jan 2021

Zhu Mingyu, Zhang Lu, Cui Haiyan, Zhao Qiang, Wang Hao, Zhai Baochao, Jiang Richeng, Jiang Zhansheng

Abstract excerpt

Immunotherapy based on immune checkpoint inhibitors (ICIs) have demonstrated remarkable survival benefits and gained regulatory approval in non-small cell lung cancer (NSCLC) patients without an actionable driver mutation, but currently there is no well-established standard for how to screen the most suitable population for ICIs treatment. Here, we conducted a comprehensive analysis of the somatic mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Cadherins

Share to Epidermal Growth Factor

Share to Immunotherapy

Share to Lymphocytes, Tumor-Infiltrating

Share to Receptors, LDL

Source

Open in PubMed Open full text

Identifiers

PMID: 35069585
DOI: 10.3389/fimmu.2021.800951
PMCID: PMC8770854

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.PMID 35069585Read ↗

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.Semantic proximity Read ↗

Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancerSemantic proximity Read ↗

Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.Semantic proximity Read ↗

Prognostic value and antitumor immune response elicited by FAT3 and LRP1B co-mutation in endometrial cancerSemantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Genomic characteristics and immune landscape of super multiple primary lung cancer.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung AdenocarcinomaSemantic proximity Read ↗

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.